Systematic ReviewResearchPatient EducationMedication Safety

Pediatric iodine supplementation showed selective benefits, but evidence was sparse

The Cochrane database of systematic reviews (PubMed)Sep 10, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

A Cochrane review of eight randomized trials found a slight cognitive-function improvement with iodine supplementation and likely reductions in hypothyroidism and infant mortality, but each of those findings came from a single trial and important safety outcomes were not reported.

What NurseJet pulled from the source

The review included 2,528 participants. Cognitive function improved slightly in one study of 166 children; hypothyroidism was reduced in one study of 264 participants, and all-cause mortality was reduced in one infant study of 617 participants.

Why this matters for nurses

Iodine deficiency prevention is important for growth and neurodevelopment, but the review shows that several clinically important conclusions rest on one trial and that harms were not adequately reported.

Bedside takeaway

Avoid one-size-fits-all supplementation advice; key benefits came from single trials and harms were not reported.

Key takeaways

Iodine supplementation may make little or no difference to weight, based on three studies with 658 participants and low-certainty evidence.
The effect on goitre was very uncertain because the two-study estimate was imprecise and highly heterogeneous.
No included study reported iodine-related adverse events or health-related quality of life.

Practice implications

Assess diet and supplement use during pediatric teaching, and reinforce only the iodine strategy recommended by the patient's clinician, local public-health program, or facility protocol.

Limitations & cautions

Abstract-only summary. The eight trials used widely differing ages, doses, routes, and follow-up periods; several key outcomes came from one trial, and adverse-event data were absent.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

The Cochrane database of systematic reviews (PubMed)

The Cochrane database of systematic reviews (PubMed). Iodine supplementation for preventing iodine deficiency disorders in children and adolescents.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42720098/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Journal of pediatric nursing (PubMed)Oct 23, 2026Research Article

A randomized controlled trial of 140 children aged 3–6 years in a pediatric emergency department found that using a dragon-themed nebulizer mask significantly decreased child fear scores (d = 3.05) and shortened treatment duration compared with standard clear masks.

Peds EmergencyAI summaryReview source

Research ArticleResearchWorkflowQuality ImprovementAI summary · original source linked below

Inhalation therapy is frequently administered for acute respiratory distress in emergency settings, yet standard plastic masks often provoke intense fear and noncooperation in young children, prolonging treatment. In this parallel-group randomized controlled trial conducted between January and March 2026 at a tertiary pediatric emergency department in Istanbul (NCT06568120), 140 preschool children aged 3 to 6 years requiring nebulizer therapy were randomized 1:1 to either a dragon-themed colorful nebulizer mask (n=70) or a standard clear mask control group (n=70). A researcher-nurse recorded procedural metrics using a Demographic Information Form, the Fear Scale, and a Treatment Duration and Adherence Assessment Form. While baseline demographics were comparable (p > 0.05), children in the dragon-themed mask group experienced significantly lower fear scores (p < 0.001, Cohen d = 3.05; 95% CI: 2.56–3.54) and significantly shorter inhalation treatment durations (p = 0.012, Cohen d = 0.47; 95% CI: 0.14–0.81). Observed behavioral distress responses—such as crying, verbal refusal, anger, or mask removal attempts—did not differ significantly between groups (all p > 0.05).

Key takeaways

Parallel-group RCT randomized 140 preschool children aged 3–6 requiring nebulizer therapy in a tertiary pediatric ED to a dragon-themed mask or standard mask.
Children receiving nebulization via the dragon-themed mask demonstrated markedly lower procedural fear scores (p < 0.001, Cohen d = 3.05).
Treatment application duration was significantly reduced in the dragon-themed mask group (p = 0.012, Cohen d = 0.47).
Overt behavioral resistance measures (crying, anger, active mask displacement) were statistically similar between groups (p > 0.05).
Findings support low-cost, child-friendly design adaptations to standard emergency respiratory equipment to diminish pediatric fear and improve workflow.

Why this matters on shift

Pediatric emergency and clinic nurses frequently encounter acute distress, terror, and combative resistance from young children during aerosolized medication delivery. When children scream or fight the mask, drug pulmonary deposition drops sharply and treatment stretches out. Demonstrating that an inexpensive, themed visual mask substantially cuts fear scores and speeds up delivery provides bedside nurses an immediate, non-pharmacological strategy to improve shift efficiency and soothe pediatric patients.

Bedside takeaway

In a 140-child pediatric ED RCT, a dragon-themed nebulizer mask significantly lowered fear scores (d = 3.05) and shortened inhalation duration (p = 0.012) compared to standard masks in children aged 3–6.

Nursing implications

When initiating aerosolized bronchodilator or steroid therapy in preschool-age children, introduce child-friendly themed masks or gamified distraction to alleviate fear; secure an adequate seal around the nose and mouth while reassuring the child and caregiver throughout the nebulization cycle.

Limitations & cautions

Conducted at a single tertiary center in Turkey; open-label delivery precluded blinding of children, caregivers, and administering nurses; overt behavioral distress metrics showed no statistically significant between-group divergence.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of pediatric nursing (PubMed). The effect of using a dragon-themed nebulizer mask on treatment application duration, adherence, and fear in children presenting to the emergency department: A randomized controlled trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Internal and emergency medicine (PubMed)Oct 20, 2026Research Article

A multicenter triple-blind randomized controlled trial of 73 emergency department patients found intravenous ibuprofen (800 mg) produced significantly greater pain score reductions at 10 and 30 minutes and shorter ED stays compared with intravenous ketorolac (30 mg).

Emergency Med-SurgAI summaryReview source

Research ArticleResearchMedication SafetyWorkflowAI summary · original source linked below

Acute low back pain (LBP) accounts for high emergency department utilization, yet clinicians continually seek non-opioid parenteral analgesics that provide rapid, dependable relief without prohibitive adverse profiles. In this multicenter, triple-blind randomized clinical trial conducted across three academic hospital emergency departments, 73 adult patients presenting with acute LBP were randomized to receive either intravenous ibuprofen (800 mg, n=34) or intravenous ketorolac (30 mg, n=39). Analgesic infusions were prepared in quadruplicate blocks by trained head nurses, maintaining blinding for patients, investigators, and biostatisticians. Pain was recorded on a 100-mm Visual Analog Scale (VAS) at baseline, 10 minutes, and 30 minutes post-infusion. Mean VAS pain scores were significantly lower in the ibuprofen arm at 10 minutes (49.6 vs 57.4; p = 0.013) and at 30 minutes (32.2 vs 40.7; p = 0.038). Furthermore, 70.6% of ibuprofen patients achieved mild pain levels by 30 minutes versus 35.9% of ketorolac recipients (p < 0.001). Mean ED length of stay was also significantly shorter in the ibuprofen cohort, while rescue analgesia requirements and drug-related adverse events did not differ between arms.

Key takeaways

Multicenter triple-blind RCT randomized 73 ED patients with acute low back pain to IV ibuprofen 800 mg (n=34) or IV ketorolac 30 mg (n=39).
IV ibuprofen yielded significantly lower VAS pain scores at both 10 minutes (49.6 vs 57.4, p = 0.013) and 30 minutes (32.2 vs 40.7, p = 0.038).
Twice as many patients achieved mild pain intensity at 30 minutes with ibuprofen compared to ketorolac (70.6% vs 35.9%, p < 0.001).
Mean ED length of stay was significantly reduced in the ibuprofen cohort, without any increase in adverse drug events or rescue analgesia.
Findings support IV ibuprofen as an effective, rapid-acting, non-opioid parenteral alternative to ketorolac for acute musculoskeletal back pain in the ED.

Why this matters on shift

Emergency nurses manage acute musculoskeletal back pain daily and frequently administer IV NSAIDs to avoid opioid exposure. Ketorolac has traditionally served as the default parenteral non-opioid, but these triple-blind findings show IV ibuprofen (800 mg) delivers faster and deeper pain reduction within the critical first 30 minutes, doubles the rate of relief down to mild pain, and facilitates earlier discharge without added complications.

Bedside takeaway

In a triple-blind ED RCT of 73 adults with acute low back pain, IV ibuprofen (800 mg) achieved lower VAS pain scores at 10 and 30 minutes and higher mild-pain rates (70.6% vs 35.9%) than IV ketorolac (30 mg).

Nursing implications

Verify renal function, volume status, GI bleeding history, and pregnancy status prior to parenteral NSAID infusion; administer IV ibuprofen over the ordered infusion time and evaluate pain response using a standardized scale at 10 and 30 minutes to determine if rescue analgesia is needed.

Limitations & cautions

Modest total sample size (73 patients) across three university centers; evaluation period concluded at 30 minutes without tracking long-term recurrence or post-discharge outcomes.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Internal and emergency medicine (PubMed). Intravenous ibuprofen versus ketorolac for acute low back pain in the emergency department: a triple-blind randomized clinical trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Journal of the American College of Cardiology (PubMed)Oct 13, 2026Research Article

The multicenter SUBCUT-HF II randomized trial of 172 hospitalized heart failure patients demonstrated that early discharge using a wearable subcutaneous furosemide minipump achieved 4.0 more days alive and out of hospital at 30 days compared with standard inpatient care.

Telemetry Med-SurgAI summaryReview source

Research ArticleResearchQuality ImprovementWorkflowAI summary · original source linked below

Patients hospitalized with decompensated heart failure frequently endure prolonged inpatient admissions solely to finish intravenous loop diuretic titration. In the multicenter, open-label, active-controlled SUBCUT-HF II randomized trial (NCT05419115) conducted across the United Kingdom, 172 patients hospitalized for heart failure who required continued parenteral diuretic therapy were randomized to an early supported discharge strategy (n=92) or usual inpatient care (n=80). The early discharge cohort received a novel pH-neutral formulation of subcutaneous furosemide administered via a wearable, patient-operated minipump, supported by outpatient clinical reviews every 3 days during active infusion, alongside a 2-week follow-up for both arms. The primary endpoint of days alive and out of hospital (DAOH) at 30 days was significantly higher in the early discharge arm (4.0 more days, 95% CI: 2.1–5.8 days; p < 0.001). Mean index hospital stay was shortened by 5.5 days (95% CI: 3.6–7.4 days; p < 0.001). This DAOH benefit was sustained through 60 days (4.2 days, 95% CI: 0.9–7.6 days), despite non-statistically significant higher heart failure readmissions in the early discharge group (14% [n=13] vs 6% [n=5]; OR: 2.45, 95% CI: 0.81–7.43). Serious adverse events occurred in 25% vs 23% of participants, and device issues arose in 3% of placements without serious sequelae.

Key takeaways

Multicenter UK randomized controlled trial (SUBCUT-HF II) evaluated 172 patients hospitalized with heart failure requiring ongoing parenteral diuresis.
Early discharge with a wearable subcutaneous furosemide minipump yielded 4.0 more days alive and out of hospital at 30 days (p < 0.001).
Mean length of index hospital stay decreased by 5.5 days (95% CI: 3.6–7.4 days, p < 0.001) in the subcutaneous minipump cohort.
Clinical benefits persisted at 60 days (4.2 additional DAOH), with comparable serious adverse event rates (25% vs 23%).
Device-related technical issues were observed in only 3% of placements, confirming the mechanical feasibility of outpatient wearable infusion.

Why this matters on shift

Cardiology and telemetry nurses spend extensive time coordinating intravenous diuretic administration, monitoring fluid balances, and planning discharge for heart failure patients who are otherwise clinically stable. Wearable subcutaneous infusion technology enables safe, out-of-hospital decongestion, liberating acute hospital beds and improving patient quality of life, but requires specialized nurse education on pump operation, infusion site care, and vigilant outpatient symptom surveillance.

Bedside takeaway

In the 172-patient SUBCUT-HF II trial, early discharge with a wearable subcutaneous furosemide minipump yielded 4.0 more days alive and out of hospital at 30 days and shortened index hospital stay by 5.5 days.

Nursing implications

Educate heart failure patients on subcutaneous minipump placement, needle insertion site inspection for local erythema or leakage, daily weights, and symptom red flags; coordinate close outpatient follow-up checks every 3 days during active subcutaneous loop diuretic titration.

Limitations & cautions

Open-label trial design; trend toward higher 30-day readmissions (14% vs 6%, OR 2.45) warrants close outpatient monitoring systems; conducted within UK National Health Service infrastructure.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of the American College of Cardiology (PubMed). Early Discharge Strategy Including Subcutaneous Furosemide in Hospitalized Heart Failure.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

Randomized trial of 140 preschool children in pediatric ED finds dragon-themed nebulizer mask substantially reduces fear and shortens treatment duration

Triple-blind randomized trial of 73 ED patients finds intravenous ibuprofen achieves superior acute pain relief compared with ketorolac for acute low back pain

Multicenter trial of 172 hospitalized heart failure patients finds wearable subcutaneous furosemide minipump strategy adds 4.0 days alive and out of hospital at 30 days